Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris.

Next Previous
Trial Profile

A Phase 2 Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT-004 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arctic Therapeutics

Most Recent Events

  • 19 Aug 2026 Status changed from active, no longer recruiting to completed.
  • 11 Feb 2026 According to Arctic Therapeutics, the company announced that the first patients have been enrolled.
  • 11 Feb 2026 According to Arctic Therapeutics, the study will be conducted across three clinical sites in Denmark and is being carried out by Blueskin, a leading European contract research organization (CRO) specializing in dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top